Tumor News and Research

RSS

New handheld probe can produce detailed images of blood vessels, other internal body parts

A new handheld probe developed by a team of university and industry researchers in the Netherlands and France could give doctors powerful new imaging capabilities right in the palms of their hands. The imaging system, which is described in a paper published in The Optical Society's open-access journal Optics Express, shrinks a technology that once filled a whole lab bench down to a computer screen and a small probe about the size of a stapler.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

ProstaCaid dietary supplement supports prostate health

A recent presentation at an international cancer research conference in Greece reviewed the body of data on ProstaCaid, a dietary supplement compound for prostate health. A number of published studies demonstrate the formula's effects in supporting prostate health against specific prostate cancer cell lines and prostate urinary symptoms.

5 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Advaxis, Inc., a cancer immunotherapy company, today announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

5 Nov 2014

Loyola study finds radiation as a risk factor for young people with meningioma

In people under age 30, radiation is a risk factor for a type of brain tumor called a meningioma, a Loyola University Medical Center study has found.

4 Nov 2014

Study reports IL-37's activity in the adaptive immune system

A University of Colorado Cancer Center study published in this month's Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body's immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens.

4 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Researchers make significant advancement in early diagnosis of invasive cancers

A team of researchers from Inserm led by Paul Hofman (Inserm Unit 1081/University of Nice) has just made a significant advance in the area of early diagnosis of invasive cancers. In a study which has just been published in the journal PLOS ONE, the team shows that it is possible to detect, in patients at risk of developing lung cancer, early signs, in the form of circulating cancer cells, several months, and in some cases several years, before the cancer becomes detectable by CT scanning.

4 Nov 2014

NSAIDs protect against colorectal cancer by inducing cell suicide pathways in intestinal stem cells

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect against the development of colorectal cancer by inducing cell suicide pathways in intestinal stem cells that carry a certain mutated and dysfunctional gene, according to a new study led by researchers at the University of Pittsburgh Cancer Institute and the School of Medicine.

4 Nov 2014

AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc., a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie’s novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

LSU Health New Orleans receives grant to support young breast cancer survivors in the Gulf South

The LSU Health New Orleans School of Public Health has been awarded a $2.2 million grant to increase the availability of health information and support services for young breast cancer survivors in the Gulf South.

4 Nov 2014

APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

In terms of duration of treatment and cost, patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) with proton therapy versus whole breast irradiation (WBI), according to new research from The University of Texas MD Anderson Proton Therapy Center.

3 Nov 2014

Rice-led research shows how migratory cancer cells acquire 'stem-like' properties

In the first study of its kind, Rice University researchers have mapped how information flows through the genetic circuits that cause cancer cells to become metastatic. The research reveals a common pattern in the decision-making that allows cancer cells to both migrate and form new tumors. Researchers say the commonality may open the door to new drugs that interfere with the genetic switches that cancer must flip to form both cancer stem cells and circulating tumor cells -- two of the main players in cancer metastasis.

31 Oct 2014

Johns Hopkins engineers invent lab device that yields microscopic look at metastasis

Johns Hopkins engineers have invented a lab device to give cancer researchers an unprecedented microscopic look at metastasis, the complex way that tumor cells spread through the body, causing more than 90 percent of cancer-related deaths. By shedding light on precisely how tumor cells travel, the device could uncover new ways to keep cancer in check.

31 Oct 2014

Study compares five-year DFS and OS rates for patients with AIS and MIA

Lung cancer patients with minimally invasive adenocarcinoma (MIA) have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ (AIS), according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Study estimates Medicare costs of lung cancer diagnostic workup in patients

Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Molecular profiling reveals potential therapeutic targets for lung cancer

Analysis of 607 small cell lung cancer (SCLC) lung tumors and neuroendocrine tumors (NET) identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Tumor News and Research

New handheld probe can produce detailed images of blood vessels, other internal body parts

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

ProstaCaid dietary supplement supports prostate health

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Loyola study finds radiation as a risk factor for young people with meningioma

Study reports IL-37's activity in the adaptive immune system

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Researchers make significant advancement in early diagnosis of invasive cancers

NSAIDs protect against colorectal cancer by inducing cell suicide pathways in intestinal stem cells

AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

LSU Health New Orleans receives grant to support young breast cancer survivors in the Gulf South

APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

Rice-led research shows how migratory cancer cells acquire 'stem-like' properties

Johns Hopkins engineers invent lab device that yields microscopic look at metastasis

Study compares five-year DFS and OS rates for patients with AIS and MIA

Data reveals sustained local control for early stage lung cancer patients who receive SBRT

Study estimates Medicare costs of lung cancer diagnostic workup in patients

Molecular profiling reveals potential therapeutic targets for lung cancer

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News